Medline Inc.

MDLN· Nasdaq· Surgical & Medical Instruments & Apparatus

Market cap
–
P/FCF
–
EV/Sales
–
FCF margin
4.6%
ROIC, 5 yr avg
–
Revenue, 5 yr CAGR
–
We record prices for the companies we cover; MDLN is not one of them yet.

Company statistics

From the 10-Ks, computed in code · point at a figure for its formula

Profile · FY2025

Market cap
–
Enterprise value
–
Diluted shares
810.0M
Revenue
$28.4B
Free cash flow
$1.3B
Owner earnings
$1.2B

Valuation · FY2025

P/E
–
P/FCF
–
P/Owner earnings
–
EV/Sales
–
EV/FCF
–
P/B
–

Margins · FY2025

Gross
26.4%
Operating
7.8%
Net
4.1%
Free cash flow
4.6%
Owner earnings
4.3%
Stock pay
0.3%

Returns

ROIC, FY2025
9.6%
ROIC, 5 yr avg
–
ROE, FY2025
10.8%
ROE, 5 yr avg
–

Growth (CAGR)

Revenue, 3 yr
–
Revenue, 5 yr
–
Revenue, 2 yr
10.6%
Diluted EPS, 3 yr
–
Diluted EPS, 5 yr
–
Diluted EPS, 2 yr
–
Free cash flow, 3 yr
–
Free cash flow, 5 yr
–
Free cash flow, 2 yr
-4.1%

Financial health · FY2025

Cash and investments
$1.9B
Total debt
$12.6B
Net debt
$10.6B
Debt/Equity
1.2x
Debt/FCF
9.7x

Shareholder returns · FY2025

Dividend yield
–
Payout ratio
–
Buyback yield
–
Shareholder yield
–
Share count, 5 yr
–

Financials: ten years from the 10-Ks

Reported numbers open their filing · computed ones show the formula · ˢ split-adjusted

Revenue

$28.4B

+10.6% a year over 2 years

FY2023: Revenue $23.2BFY2024: Revenue $25.5BFY2025: Revenue $28.4B
FY2023FY2025

Margins

Gross26.4%Operating7.8%Net4.1%

FY2025

FY2023: Gross 25.3%, Operating 5.4%, Net –FY2024: Gross 27.3%, Operating 8.4%, Net –FY2025: Gross 26.4%, Operating 7.8%, Net 4.1%
FY2023FY2025

Free cash flow and owner earnings

Free cash flow$1.3BOwner earnings$1.2B

Free cash flow -4.1% a year

FY2023: Free cash flow $1.4B, Owner earnings $1.3BFY2024: Free cash flow $1.4B, Owner earnings $1.4BFY2025: Free cash flow $1.3B, Owner earnings $1.2B
FY2023FY2025

Diluted shares

810.0M

FY2025

FY2023: Diluted shares –FY2024: Diluted shares –FY2025: Diluted shares 810.0M
FY2023FY2025

Return on invested capital

9.6%

FY2025

FY2023: ROIC –FY2024: ROIC –FY2025: ROIC 9.6%
FY2023FY2025

Net debt (below zero)

-$10.6B

$10.6B more debt than cash

FY2023: Net cash –FY2024: Net cash -$16.3BFY2025: Net cash -$10.6B
FY2023FY2025

Every figure, year by year

Fiscal yearFY2023FY2024FY2025
The business
Revenue$23.2B$25.5B$28.4B
Revenue growth–9.8%11.5%
Gross margin25.3%27.3%26.4%
Operating margin5.4%8.4%7.8%
Net income––$1.2B
Net margin––4.1%
Diluted EPS––$-0.01
Return on invested capital?––9.6%
Cash
Operating cash flow$1.7B$1.8B$1.7B
Capital expenditure$275.0M$354.0M$447.0M
Free cash flow$1.4B$1.4B$1.3B
Stock-based compensation$78.0M$61.0M$76.0M
Owner earnings?$1.3B$1.4B$1.2B
Free cash flow per share––$1.60
Capital allocation
Dividends paid–––
Share repurchases$0$20.0M$33.0M
Diluted shares––810.0M
Share count change?–––
Balance sheet
Cash and equivalents$1.6B$199.0M$1.9B
Short-term investments–––
Total debt–$16.5B$12.6B
Net debt–$16.3B$10.6B
Shareholders' equity––$10.7B

Latest filings

All on EDGAR
2026-08-0510-QQuarterly report
2026-08-058-KEarnings release
2026-05-0610-QQuarterly report
2026-05-068-KEarnings release
2026-04-23DEF 14AProxy statement
2026-02-2510-KAnnual report
2026-02-258-KEarnings release

More from our coverage

All coverage